Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a ...

AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

The most important networking command in Linux might be ping. This command lets you check if a remote machine is responding ...

A steaming bowl of pho becomes the most vivid thing in your visual field – the clear amber broth, bright green herbs, ruby red sriracha swirls, and sunny yellow lime wedges appearing almost ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has ...

DNA Ginkgo Bioworks Holdings, Inc.

Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079) -- XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine ...

Whether you’re setting out on a course of academic study that will define your professional life, or seeking to build skills to help you land a better job, Santa Clara’s graduate programs offer a ...